FDA-cleared profile

Ceevra Reveal 3

Ceevra, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Ceevra Reveal 3 processes, reviews, analyzes, communicates, and interchanges multidimensional CT and MR images for preoperative planning and intraoperative display, with preliminary machine-learning segmentations of selected normal anatomy for adult patients aged 22 years and older.

Clinical role
Multidimensional image viewing, manipulation, segmentation, planning, and intraoperative display support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Patient-specific anatomy represented in CT or MR; normal anatomy used by supported segmentation models
Key limitation
Keep in mind: Machine-learning segmentation is limited to the labeled adult age group and supported models; patients under 22 or of unknown age are outside the stated ML scope, and clinicians make final decisions.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Ceevra Reveal 3 processes, reviews, analyzes, communicates, and interchanges multidimensional CT and MR images for preoperative planning and intraoperative display, with preliminary machine-learning segmentations of selected normal anatomy for adult patients aged 22 years and older.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Patient-specific anatomy represented in CT or MR; normal anatomy used by supported segmentation models Input: Supported CT and MR DICOM studies and user-selected patient images.
  • Who uses it?Intended users: Trained radiologists, surgeons, physicians, and other qualified healthcare professionals.
  • What does the software produce?Output: Displayed images, reformats, preliminary segmentations, measurements, and planning views.
  • What is its most important limitation?Key limitation: Machine-learning segmentation is limited to the labeled adult age group and supported models; patients under 22 or of unknown age are outside the stated ML scope, and clinicians make final decisions.

Clinical takeaway. Clinical role: Ceevra Reveal 3 processes, reviews, analyzes, communicates, and interchanges multidimensional CT and MR images for preoperative planning and intraoperative display, with preliminary machine-learning segmentations of selected normal anatomy for adult patients aged 22 years and older.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation testing and verification of four machine learning segmentation models on 141 CT or MR imaging studies, with training and test data separated by scanning institution, against segmentations generated by medical professionals. Reported results include prostate (MR prostate imaging) 0.87 DSC, neurovascular bundles (MR prostate imaging) 7.8 mm HD-95 and kidney (CT abdomen imaging) 0.89 DSC. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Ceevra Reveal 3 processes, reviews, analyzes, communicates, and interchanges multidimensional CT and MR images for preoperative planning and intraoperative display, with preliminary machine-learning segmentations of selected normal anatomy for adult patients aged 22 years and older.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Multidimensional image viewing, manipulation, segmentation, planning, and intraoperative display support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT and MR DICOM studies and user-selected patient images.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Displayed images, reformats, preliminary segmentations, measurements, and planning views.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital imaging, surgical-planning, and intraoperative workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained radiologists, surgeons, physicians, and other qualified healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Machine-learning segmentation is limited to the labeled adult age group and supported models; patients under 22 or of unknown age are outside the stated ML scope, and clinicians make final decisions.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification and validation testing and verification of four machine learning segmentation models on 141 CT or MR imaging studies, with training and test data separated by scanning institution, against segmentations generated by medical professionals. Reported results include prostate (MR prostate imaging) 0.87 DSC, neurovascular bundles (MR prostate imaging) 7.8 mm HD-95 and kidney (CT abdomen imaging) 0.89 DSC. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Safety and performance of Ceevra Reveal 3 has been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "Four machine learning models are included in Ceevra Reveal 3. These models were verified with datasets of actual CT or MR imaging studies of patients. A total of 141 imaging studies were used to evaluate the device.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification and validation testing and verification of four machine learning segmentation models on 141 CT or MR imaging studies, with training and test data separated by scanning institution, against segmentations generated by medical professionals. Reported results include prostate (MR prostate imaging) 0.87 DSC, neurovascular bundles (MR prostate imaging) 7.8 mm HD-95 and kidney (CT abdomen imaging) 0.89 DSC. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Safety and performance of Ceevra Reveal 3 has been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "Four machine learning models are included in Ceevra Reveal 3. These models were verified with datasets of actual CT or MR imaging studies of patients. A total of 141 imaging studies were used to evaluate the device.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Prostate segmentation Dice coefficient on MR

0.87 Dice coefficient

  • EndpointNormal-anatomy segmentation agreement
  • PopulationCeevra Reveal 3 MR verification studies
  • Tested versionCeevra Reveal 3 configuration described in K222676

Kidney segmentation Dice coefficient on CT

0.89 Dice coefficient

  • EndpointNormal-anatomy segmentation agreement
  • PopulationCeevra Reveal 3 CT verification studies
  • Tested versionCeevra Reveal 3 configuration described in K222676

K222676 FDA evidence package for Ceevra Reveal 3

  • DesignFDA 510(k) software verification and validation of four machine-learning segmentation models with institution-level separation of development and testing data.
  • PopulationCT and MR imaging studies used to verify the exact Ceevra Reveal 3 segmentation models.
  • Scopeexact submission
  • Tested versionCeevra Reveal 3 configuration described in K222676
  • Samplen=141
  • IndependenceSponsor or vendor study

K222676

The FDA package reports 141 imaging studies and structure-specific Dice or Hausdorff results; preliminary segmentations require clinician review.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K222676 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT and MR DICOM studies and user-selected patient images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K222676: Ceevra Reveal 3

  2. Routing

    Source context, not route validation: The FDA package describes multidimensional CT and MR image input and mobile, desktop, or virtual-reality viewing paths.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K222676: Ceevra Reveal 3

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Displayed images, reformats, preliminary segmentations, measurements, and planning views.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K222676: Ceevra Reveal 3

  5. Viewer/worklist/report

    Unresolved route: Displayed images, reformats, preliminary segmentations, measurements, and planning views.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K222676: Ceevra Reveal 3

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA package describes multidimensional CT and MR image input and mobile, desktop, or virtual-reality viewing paths.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only trained radiologists, surgeons, physicians, and other qualified healthcare professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K222676 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Machine-learning segmentation is limited to the labeled adult age group and supported models; patients under 22 or of unknown age are outside the stated ML scope, and clinicians make final decisions.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K222676 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes multidimensional CT and MR image input and mobile, desktop, or virtual-reality viewing paths.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Machine-learning segmentation is limited to the labeled adult age group and supported models; patients under 22 or of unknown age are outside the stated ML scope, and clinicians make final decisions.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K222676 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Machine-learning segmentation is limited to the labeled adult age group and supported models; patients under 22 or of unknown age are outside the stated ML scope, and clinicians make final decisions.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. multimodality medical-image visualization software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K222676
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Patient-specific anatomy represented in CT or MR; normal anatomy used by supported segmentation models
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-04-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K222676: Ceevra Reveal 3

    U.S. Food and Drug Administration - Published 2023-04-25 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Ceevra Reveal 3 model card (K222676)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K222676 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253969

ADAS 3D

Adas3D Medical S.L.

Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Heart; myocardial scar and cardiac structures
Decision
2026-06-29
FDA-cleared K260316

CMN Capillary Function with Oncology Virtual Expert

Cercare Medical A/S

Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-06-22
FDA-cleared K261713

Synapse PACS (7.6.0)

FUJIFILM Healthcare Americas Corporation

Synapse PACS 7.6.0 provides medical-image management and processing, including measurements, regional segmentation, clinical calculations, structured reports, comparison, fusion, and volume rendering to aid reading, interpretation, reporting, and treatment planning.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
N/A
Decision
2026-06-18
FDA-cleared K252563

Neurophet SCALE PET

Neurophet., Inc.

Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-05-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history